PROGNOSTIC IMPACT OF BONE MARROW FIBROSIS IN PRIMARY MYELODYSPLASTIC SYNDROMES

RUSSO, MARIA FLORENCIA; BELLI, CAROLINA; ENRICO, ALICIA; ARBELBIDE, JORGE; NARBAITZ, MARINA; DE DIOS SOLER, MARCELA; GARCIA RIVELLO, HERNAN; MARTIN, CARLOS; IASTREBNER, MARCELO; GONZALEZ, JACQUELINE; ROSENHAIN, MARIANA; ALFONSO, GRACIELA; KORNBLIHTT, LAURA; PERUSINI, MARIA AGUSTINA; LAZZARINO, CAROLINA

Virtual

Congreso; 26th Congress of the European Hematology Association; 2021

European Haematology Association

BackgroundMyelofibrosis (MF) is observed in 10-20% of patients with myelodysplastic syndrome (MDS). The presence of MF≥2 according to the European Myelofibrosis Network (EUMNET 2005) has been recognized as an adverse histological finding associated with an aggressive course including early bone marrow failure, shortened survival and leukemic evolution. According to a previous survey performed by our group, the bone marrow biopsy is the most available complemental study in our media. Therefore improving the knowledge of variables related with MF and their prognostic role in patients with MDS is highly desirable. AimsTo examine the influence of the presence of any degree of myelofibrosis (MF≥1) in overall survival (0S) in an Argentine MDS cohort and its association with clinical and histopathologic variables such as percentage of blasts, bone marrow cellularity, atypical erythroid localization and dysplastic megakaryocytes.MethodsWe identified 468 MDS patients from a multicentric retrospective database of 706 patients who were included in the Argentinian Registry of MDS from 2007 to 2017, with recorded evaluation of MF in the bone marrow biopsy. Statistical analysis included Kaplan-Meier and log rank test, Cox proportional hazard and Logistic regression.ResultsFrom the selected cohort, 32.7% had MF≥1, 25.8% (n=121) with MF-1, 5.7% (n=27) with MF-2 and 1% (n=5) had MF-3. When analyzing the characteristics of the population, we observe that the median age of these patients was 70 years old (Interquartile range 60-78) being 66.1% >65 years old and 55.8% were males. At the time of diagnosis we observe: median hemoglobin 9.0g/dL, platelet counts 121.500/mL and neutrophils 1.800/µL; 25.7% poor karyotypes and 26.7% IPSS-R>3.5.The median overall survival (OS) of the MF≥1 subgroup was 20.1 months (95% CI 10.1-30.0, p